We recently demonstrated that stimulation of gp130 by a combination of soluble interleukin 6 receptor (sIL-6R) and IL-6 but not IL-6 alone significantly stimulates the ex vivo expansion of primitive hematopoietic progenitors and the generation of erythroid cells from human CD34+ cells in the presence of stem cell factor (SCF). Here, we show that gp130 is found low positively on most CD34+ cells, whereas IL-6R is expressed on only 30-50% of these cells. Although most of the colonies generated from FACS-sorted CD34+IL-6R+ cells were granulocyte/macrophage (GM) colonies, CD34+IL-6R- cells gave rise to various types of colonies, including erythroid bursts, GM, megakaryocytes, and mixed colonies in methylcellulose culture with a combination of IL-6, sIL-6R, and SCF. Similar results were obtained in culture supplemented with a combination of IL-3, IL-6, SCF, granulocyte colony-stimulating factor, erythropoietin, and thrombopoietin. A limiting dilution analysis of long-term culture-initiating cells (LTC-IC) showed that the CD34+IL-6R- cells contained a larger number of LTC-IC than did the CD34+IL-6R+ cells. In a serum-free suspension of CD34+IL-6R- cells, the addition of sIL-6R to the combination of IL-6 and SCF dramatically increased the total and multipotential progenitors, whereas CD34+IL-6R+ cells failed to do so under the same conditions. These results indicate that most of the erythroid, megakaryocytic, and primitive human hematopoietic progenitors are included in the IL-6R- populations, and the activation of gp130 on these progenitors can be achieved by a complex of IL-6-sIL-6R, but not by IL-6 alone. The present culture system using IL-6, sIL-6R, and SCF may provide a novel approach for ex vivo expansion of human primitive hematopoietic progenitors.
Article|
October 01 1996
Analysis of interleukin 6 receptor and gp130 expressions and proliferative capability of human CD34+ cells.
S Tajima,
S Tajima
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
K Tsuji,
K Tsuji
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
Y Ebihara,
Y Ebihara
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
X Sui,
X Sui
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
R Tanaka,
R Tanaka
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
K Muraoka,
K Muraoka
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
M Yoshida,
M Yoshida
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
K Yamada,
K Yamada
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
K Yasukawa,
K Yasukawa
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
T Taga,
T Taga
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
T Kishimoto,
T Kishimoto
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
T Nakahata
T Nakahata
Department of Clinical Oncology, University of Tokyo, Japan.
Search for other works by this author on:
S Tajima
Department of Clinical Oncology, University of Tokyo, Japan.
K Tsuji
Department of Clinical Oncology, University of Tokyo, Japan.
Y Ebihara
Department of Clinical Oncology, University of Tokyo, Japan.
X Sui
Department of Clinical Oncology, University of Tokyo, Japan.
R Tanaka
Department of Clinical Oncology, University of Tokyo, Japan.
K Muraoka
Department of Clinical Oncology, University of Tokyo, Japan.
M Yoshida
Department of Clinical Oncology, University of Tokyo, Japan.
K Yamada
Department of Clinical Oncology, University of Tokyo, Japan.
K Yasukawa
Department of Clinical Oncology, University of Tokyo, Japan.
T Taga
Department of Clinical Oncology, University of Tokyo, Japan.
T Kishimoto
Department of Clinical Oncology, University of Tokyo, Japan.
T Nakahata
Department of Clinical Oncology, University of Tokyo, Japan.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1996) 184 (4): 1357–1364.
Citation
S Tajima, K Tsuji, Y Ebihara, X Sui, R Tanaka, K Muraoka, M Yoshida, K Yamada, K Yasukawa, T Taga, T Kishimoto, T Nakahata; Analysis of interleukin 6 receptor and gp130 expressions and proliferative capability of human CD34+ cells.. J Exp Med 1 October 1996; 184 (4): 1357–1364. doi: https://doi.org/10.1084/jem.184.4.1357
Download citation file: